On October 2, GRAIL, Inc. fell 5.07% in regular trading, trading around $132.38/share, with turnover of approximately $121 million. The decline came as short-term profit-taking pressure emerged following a sharp rally driven by the FDA advisory committee's favorable vote on the company's Galleri multi-cancer early detection test.

On September 23, the FDA Molecular and Clinical Genetics Devices Panel voted unanimously 10-0 on Galleri's safety, 6-4 in favor of its efficacy, and 7-2 (with one abstention) that its clinical benefits outweigh risks for adults aged 50 and older. The positive outcome had propelled GRAIL shares sharply higher since late September, with the stock surging over 34% in a single session when FDA briefing documents were first released. UBS, which maintains a Buy rating, stated the committee vote nearly \"de-risked\" the approval pathway. However, the advisory committee's recommendation is non-binding, and the final FDA approval decision remains pending, likely in the first half of next year.

With the committee catalyst now largely priced in, the pullback reflects natural consolidation. RBC Capital Markets has flagged potential adoption and reimbursement hurdles that could limit near-term commercial ramp even if formal approval is granted.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)